Bionor Pharma Announces that the Combination of Vacc-4x + Revlimid® is Well Tolerated and Increases CD4 Counts in People Living with HIV
(Oslo, Norway, 17 November 2014) Bionor Pharma ASA (OSE:BIONOR) announces the results from the Vacc-4x + Revlimid (lenalidomide) study also known as the “Boost & Kill” study. The Phase II trial was an exploratory double-blind placebo controlled immunogenicity study of Vacc-4x + Revlimid versus Vacc-4x in HIV subjects on ART (HIV standard of care treatment). …